Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors

Annals of Nuclear Medicine

Volumn 20, Issue 10, 2006, Pages 671-675

  Hamada, Kenichiro ^a,b   Tomita, Yasuhiko ^a   Ueda, Takafumi ^a   Enomoto, Keisuke ^a   Kakunaga, Shigeki ^a   Myoui, Akira ^a   Higuchi, Ichiro ^a   Yoshikawa, Hideki ^a   Hatazawa, Jun ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

2 deoxy 2 18F fluoro D glucose; Positron emission tomography; Soft tissue tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE TUMOR; WHOLE BODY PET; DIFFERENTIAL DIAGNOSIS; EVALUATION; FEMALE; IMAGE ENHANCEMENT; MALE; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; TIME FACTORS;

EID: 33846483137     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984678     Document Type: Article

References (12)

1. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32 (4): 623-648; discussion 49-50.
2. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Tokunaga M, Koyama Y, et al. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses. Skeletal Radiol 2003; 32 (3): 133-138.
3. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29 (2): 181-186.
4. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26 (10): 1345-1348.
5. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28 (6): 696-703.
6. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43 (7): 871-875.
7. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000 15; 89 (12): 2547-2554.
8. Alenius S, Ruotsalainen U. Bayesian image reconstruction for emission tomography based on median root prior. Eur J Nucl Med 1997; 24 (3): 258-265.
9. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32 (8): 1508-1512.
10. Griffeth LK, Dehdashti F, McGuire AH, McGuire DJ, Perry DJ, Moerlein SM, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 1992; 182 (1): 185-194.
11. Hamada K, Ueda T, Higuchi I, Inoue A, Tamai N, Myoi A, et al. Peripheral nerve schwannoma: two cases exhibiting increased FDG uptake in early and delayed PET imaging. Skeletal Radiol 2005; 34 (1): 52-57.
12. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26 (1): 22-30.